Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency by Straaten, S. van et al.
Worldwide study of hematopoietic allogeneic stem
cell transplantation in pyruvate kinase deficiency
Pyruvate kinase deficiency (PKD) is the most frequent
glycolytic enzyme defect causing hereditary non-sphero-
cytic hemolytic anemia.1 PKD leads to energy depriva-
tion of the red cell, ultimately resulting in premature red
cell death. Premature red cell death causes clinical symp-
toms of hemolytic anemia. The degree of hemolysis can
vary widely, from very mild and fully compensated
forms to life-threatening anemia with transfusion
dependency.2 The treatment for PKD is mainly support-
ive, and consists of regular red blood cell transfusions,
splenectomy and chelation therapy for iron overload.3
Hematopoietic allogeneic stem cell transplantation
(HSCT) has the potential to cure PKD. However, there is
little experience of applying HSCT in PKD. The current
knowledge of HSCT in PKD is predominantly based on
animal studies, and guidelines are not available.4,5 To
date, only four human cases of HSCT have been pub-
lished in the literature.6-8 The total number of cases trans-
planted worldwide is unknown.
The aim of this study is to make a worldwide invento-
ry of PKD cases that have been treated by HSCT, and to
evaluate indication, procedures employed and outcome
as a first step towards the establishment of guidelines for
HSCT in PKD. In order to achieve this goal queries were
sent to national and international databanks, including
the European Society for Blood and Marrow
Transplantation (EBMT), the Center for International
Blood and Marrow Transplant Research (CIBMTR), and
the National Institute of Health (NIH), as well as to
physicians known to be involved in HSCT in PKD
patients. For each case found, a specifically designed
questionnaire was sent to the physician involved. The
questionnaire contained questions on disease character-
istics, pre-transplant condition, transplant regimen and
post-transplant outcome.9 All data were evaluated by an
experienced physician, and institutions were contacted
in case of inconsistencies. An adapted EBMT score (i.e.,
age, donor type and donor-recipient sex combination)
was calculated based on the answers provided.10 In addi-
tion, data from two additional cases, published recently,
were extracted from the literature and included.8 To the
best of our knowledge, we have included all cases
worldwide.
In total, 16 cases were found to be treated by HSCT
between 1996 and 2015. Patient characteristics are sum-
marized in Table 1. Patients had all been treated in either
European or Asian centers. No cases resulted as being
transplanted in the USA. Patient’s median age at trans-
plantation was 6.5 years. All patients were transfusion-
dependent before transplantation, with median transfu-
sion needs of 13 units of packed red blood cells per year
(range: 6 to 34 units). 
Conditioning and prophylaxis characteristics are sum-
marized in Table 1. All patients received graft-versus-host
disease (GvHD) prophylaxis. Ex vivo T-cell depletion was
performed in one transplant. In another, red cell deple-
tion was performed. Five transplants were sex-matched,
four were female receiver-male donor and four were
male receiver-female donor; this information was not
available for three cases. 
Median follow-up time after transplantation was 2.3
years (range: 2 months to 19 years). Fifteen patients
showed engraftment. The sixteenth patient initially
showed pancytopenia and mixed chimerism. Following
splenectomy six months post-transplantation, this
patient's cell count spontaneously transitioned to nor-
mal with full donor chimerism. Two patients suffered
from secondary graft loss; in one there was recovery to
91% donor chimerism after donor lymphocyte infusion.
The outcome in the second patient was unknown.
Infectious complications and occurrence of GvHD are
summarized in Table 1. The most significant infectious
complications were aspergillus pneumonia (two
patients), suspected aspergillus pneumonia (one patient),
suspected fungal pneumonia (one patient), pneumonia
(one patient), sepsis (one patient) and bacterial infection
e causa ignota (one patient). GvHD grade 4 was reported
in 6/16 cases (38%). Seven out of 16 cases (44%) did not
show symptoms of GvHD. There was no correlation
between GvHD prophylaxis or any other clinical factors
and the occurrence of GvHD grade 2-4 in these patients.
Five out of 16 patients (31%) did not survive. All died
of transplant-related causes. They had a median survival
time of 13 months (range: 2-25 months).  The two-year
cumulative survival was 74%. Two patients had not yet
reached the two-year milestone at the time of the ques-
tionnaire. The three-year cumulative survival rate was
65% (Figure 1); seven patients had not yet reached the
three-year milestone.
Patients who did not survive differed significantly
from surviving patients. (Figure 1, Table 2). They were
significantly older (P=0.036). Nine out of ten patients
(90%) <10 years of age survived transplantation, where-
as two out of six (33%) ≥10 survived. Patients <10 years
were less often splenectomized (P=0.001) and had lower
pre-transfusion hemoglobin levels prior to HSCT
(P=0.04). Patients who did not survive had all been treat-
ed in European centers. All patients treated in Asian cen-
ters survived transplantation (8/8). Patients treated in
Asian centers were younger (P=0.001), less often
splenectomized (P=0.041), and had lower ferritin levels
prior to HSCT (P=0.048). In addition, they were more
often transplanted using peripheral blood stem cells as a
source (P=0.014) and more often conditioned on a
cyclophosphamide regimen (P=0.007). Furthermore,
patients who did not survive had frequently suffered
from GvHD grade 2-4 (P=0.031). Notably, four out of
five deceased patients had suffered from both GvHD
grade 3-4 and infection or viral reactivation.
There were no significant differences in sex, plasma
ferritin level, use of pre-transplant chelation therapy,
transfusion burden in the 12 months prior to HSCT,
adapted EBMT-score, conditioning regimen, relation to
donor, graft type, donor-recipient sex combination, or
transplant source.
In conclusion, herein we discuss the first global study
on the outcome of all patients known to have undergone
HSCT in PKD. Since guidelines for HSCT in PKD are
lacking, this report may be a helpful first step toward
future protocols. Compared to published survival rates
for other forms of hereditary anemias, cohorts that are
otherwise comparable in age, time period and transplant
hospital, the overall survival rate after HSCT in PKD is
relatively low.11-13 The present analysis of all 16 PKD
patients known to be transplanted to date showed a
three-year overall survival of 65%. Significantly better
survival was observed for patients transplanted before
the age of ten. A negative effect of age on survival is also
reported for other forms of hereditary anemia.11,12
Concurrently, we noticed a striking difference in survival
between patients treated in Asian and European centers,
which could possibly be explained by the difference in
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Asian patients were non-splenectomized in many
instances, and had lower pre-transplantation ferritin lev-
els, which could also be related to the young age at
which HSCT was performed. 
Asian patients were more frequently transplanted
with peripheral blood stem cells as opposed to bone
marrow-derived stem cells. Peripheral blood stem cells
are easier to collect from the donor, but reportedly
increase the risk of chronic GvHD.14 Our cohort, howev-
er, was too small to analyze the specific effect of stem
cell source on the occurrence of chronic GvHD.
An important limitation of this study is its retrospec-
tive character, and the fact that the small sample size did
not allow us to perform post hoc correction for multiple
testing. Therefore, the quantitative analysis of this data
should be interpreted with care. Other limitations
include the heterogeneity of conditioning regimens, and
heterogeneity in the pre-transplant risk classification
systems used. However, we did observe a better survival
for patients transplanted prior to age ten. This effect of
age might also play a role in the observed differences in
survival between patients treated in European centers
and those treated in Asian centers.
Although HSCT should be considered an investiga-
tional treatment, the strong decline in survival of treated
patients  over the age of ten suggests the need to evalu-
haematologica 2018; 103:e85
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Table 2. Statistical differences between surviving and non-surviving patients.
                                                                                            Survivor                                               Non-survivor                                 P value
Age in years                                                                                 7.5 – 3.0 (0.8-41)                                             17.4 – 15.2 (6-39)                                     0.036*
Asian hospital                                                                                   8/11 (73%)                                                                 0/5                                                   0.026*
Splenectomy performed                                                               3/11 (27%)                                                           4/5 (80%)                                              0.106
Mean Hb (g/dL) (N=13)                                                          6.0 – 5.5 (4,5-7,9)                                              7.1 – 6.9 (6.0-8.1)                                      0.112
Pre-transplant ferritin (ng/ml) (n=12)                            804 – 771 (206-1650)                                      2167 – 675 (596-7026)                                  0.432
Myeloablation                                                                                   6/11 (55%)                                                           4/5 (80%)                                              0.588
Graft type                                                                                                                                                                                                                                         0.507
MSD                                                                                                  2/11 (18%)                                                                 0/5                                                         
MUD                                                                                                 6/11 (55%)                                                           3/5 (60%)                                                   
CORD                                                                                               2/11 (18%)                                                                 0/5                                                        
MFD                                                                                                   1/11 (9%)                                                            2/5 (40%)                                                   
Transplant source                                                                                                                                                                                                                          0.333
Bone marrow                                                                                  4/11 (36%)                                                           4/5 (80%)                                                   
Peripheral blood                                                                            5/11 (45%)                                                           1/5 (20%)                                                   
Cord blood                                                                                      2/11 (18%)                                                                 0/5                                                         
GvHD                                                                                                                                                                                                                                                0.015*
None                                                                                                 7/11 (64%)                                                                 0/5                                                         
Grade 1                                                                                              1/11 (9%)                                                                  0/5                                                         
Grade 2                                                                                              1/11 (9%)                                                                  0/5                                                         
Grade 3                                                                                                   0/11                                                                 1/5 (20%)                                                   
Grade 4                                                                                            2/11 (18%)                                                           4/5(80%)                                                   
(descriptive statistics: mean – median (range) (N), frequencies number/total (percentage)
*P<0.05                                                                                                                                                                                                                                              
Continuous variables were expressed as mean, median and range, and subgroups were compared using Mann-Whitney U tests. Categorical data was compared using
Fisher’s exact test for binomial and the Fisher-Freeman-Halton exact test for contingency tables larger than 2x2. Statistical significance was considered as P≤0,05. All tests
were two-sided. Post hoc multiple comparison correction was not applied.Graft-versus-host disease (GvHD) is defined and graded according to international criteria.15 Pre-
transplant laboratory results from splenectomized patients are from the period after splenectomy. Hb: hemoglobin; MUD: matched unrelated donor; MSD: matched sibling
donor; MFD: matched family donor; Cord; cord blood. 
Figure 1. Overall survival, according to age.
ate HSCT as a treatment option early in life. However,
since the rate of grade 3-4 GvHD was relatively high
(7/16 = 44%), and death resulting from GvHD was like-
wise high (5/16 = 31%), transfusion dependency alone
should not be an indication for performing HSCT in
PKD.
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